Clinical potential and current progress of mesenchymal stem cells for Parkinson’s disease: a systematic review

Chen, Ying; Shen, Jiabing; Ke, Kaifu; Gu, Xiaoyong

doi:10.1007/s10072-020-04240-9

Cited by 30 publications

(16 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The potential therapeutic benefit of MSC therapy relies primarily on paracrine actions. 39 , 40 In this study, multiple peripheral markers were assessed to elucidate possible mechanisms of action. Our findings suggest a reduction in serum levels of TNF‐α and CCL22, with an increase in BDNF.…”

Section: Discussionmentioning

confidence: 99%

Allogeneic Bone Marrow–Derived Mesenchymal Stem Cell Safety in Idiopathic Parkinson's Disease

et al. 2021

View full text Add to dashboard Cite

A BS TRACT: Background: Neuroinflammation plays a key role in PD pathogenesis, and allogeneic bone marrow-derived mesenchymal stem cells can be used as an immunomodulatory therapy. Objective: The objective of this study was to prove the safety and tolerability of intravenous allogeneic bone marrow-derived mesenchymal stem cells in PD patients. Methods: This was a 12-month single-center openlabel dose-escalation phase 1 study of 20 subjects with mild/moderate PD assigned to a single intravenous infusion of 1 of 4 doses: 1, 3, 6, or 10 × 10 6 allogeneic bone marrow-derived mesenchymal stem cells/kg, evaluated 3, 12, 24, and 52 weeks postinfusion. Primary outcome safety measures included transfusion reaction, study-related adverse events, and immunogenic responses. Secondary outcomes included impact on peripheral markers, PD progression, and changes in brain perfusion.

show abstract

Section: Discussionmentioning

confidence: 99%

Allogeneic Bone Marrow–Derived Mesenchymal Stem Cell Safety in Idiopathic Parkinson's Disease

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Moreover, functional connectivity between the substantia nigra and striatum was visualized by MRI. [ 123 ]…”

Section: Experimental Attempts To Use Mesenchymal Stem Cells In the Tmentioning

confidence: 99%

Mesenchymal Stem Cells for Neurological Disorders

et al. 2021

View full text Add to dashboard Cite

Neurological disorders are becoming a growing burden as society ages, and there is a compelling need to address this spiraling problem. Stem cell‐based regenerative medicine is becoming an increasingly attractive approach to designing therapies for such disorders. The unique characteristics of mesenchymal stem cells (MSCs) make them among the most sought after cell sources. Researchers have extensively studied the modulatory properties of MSCs and their engineering, labeling, and delivery methods to the brain. The first part of this review provides an overview of studies on the application of MSCs to various neurological diseases, including stroke, traumatic brain injury, spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, Parkinson's disease, and other less frequently studied clinical entities. In the second part, stem cell delivery to the brain is focused. This fundamental but still understudied problem needs to be overcome to apply stem cells to brain diseases successfully. Here the value of cell engineering is also emphasized to facilitate MSC diapedesis, migration, and homing to brain areas affected by the disease to implement precision medicine paradigms into stem cell‐based therapies.

show abstract

“…More than 500 clinical research on MSC is underway in the world for various target diseases, including rheumatoid arthritis, systemic lupus erythematosus, Crohn’s disease, myocardial infarction, Parkinson’s disease, spinal cord injury, osteoarthritis, and graft-versus-host disease (GVHD) [ 257 , 258 , 259 , 260 , 261 , 262 , 263 , 264 , 265 , 266 ]. MSCs other than those derived from bone marrow are also being clinically applied.…”

Section: Clinical Use Of Msc-evsmentioning

confidence: 99%

Therapeutic Strategy of Mesenchymal-Stem-Cell-Derived Extracellular Vesicles as Regenerative Medicine

Matsuzaka

Yashiro

2022

IJMS

View full text Add to dashboard Cite

Extracellular vesicles (EVs) are lipid bilayer membrane particles that play critical roles in intracellular communication through EV-encapsulated informative content, including proteins, lipids, and nucleic acids. Mesenchymal stem cells (MSCs) are pluripotent stem cells with self-renewal ability derived from bone marrow, fat, umbilical cord, menstruation blood, pulp, etc., which they use to induce tissue regeneration by their direct recruitment into injured tissues, including the heart, liver, lung, kidney, etc., or secreting factors, such as vascular endothelial growth factor or insulin-like growth factor. Recently, MSC-derived EVs have been shown to have regenerative effects against various diseases, partially due to the post-transcriptional regulation of target genes by miRNAs. Furthermore, EVs have garnered attention as novel drug delivery systems, because they can specially encapsulate various target molecules. In this review, we summarize the regenerative effects and molecular mechanisms of MSC-derived EVs.

show abstract

Clinical potential and current progress of mesenchymal stem cells for Parkinson’s disease: a systematic review

Cited by 30 publications

References 60 publications

Allogeneic Bone Marrow–Derived Mesenchymal Stem Cell Safety in Idiopathic Parkinson's Disease

Allogeneic Bone Marrow–Derived Mesenchymal Stem Cell Safety in Idiopathic Parkinson's Disease

Mesenchymal Stem Cells for Neurological Disorders

Therapeutic Strategy of Mesenchymal-Stem-Cell-Derived Extracellular Vesicles as Regenerative Medicine

Contact Info

Product

Resources

About